Chronic Inflammation and Cancer: A Deep Dive into Mechanisms, Therapies, and Future Directions

Chronic inflammation is increasingly recognized not merely as a consequence of cancer, but as a key driver of its development, progression, and resistance to therapy. While acute inflammation is a vital part of the body’s immune response, persistent, unresolved inflammation creates a tumor-permissive microenvironment, fostering all stages of tumorigenesis. Recent advances in understanding the complex interplay between inflammation and cancer are paving the way for novel therapeutic strategies, particularly when integrated with immunotherapy and guided by advanced biomarker analysis.

The Inflammatory Landscape of Cancer

Since the 19th-century observations by Rudolf Virchow, the link between inflammation and cancer has been established. Currently, it’s estimated that up to 20% of all cancers are linked to chronic infections, autoimmune diseases, or environmental exposures that induce persistent inflammation ¹. This inflammation impacts not only tumor initiation but also its growth, spread, and response to treatment.

Key Signaling Pathways

Several signaling pathways are central to inflammation-driven cancer. The NF-κB and STAT3 pathways are frequently activated, promoting tumor cell survival, angiogenesis (the formation of new blood vessels), and immunosuppression ². The COX-2/PGE2 pathway also plays a significant role, driving tumor cell proliferation and the recruitment of myeloid-derived suppressor cells (MDSCs).

Immune Cell Dynamics

The tumor microenvironment (TME) is often infiltrated with immune cells that paradoxically support tumor growth. These include tumor-associated macrophages (TAMs) – particularly the M2-polarized subtype – MDSCs, regulatory T cells (Tregs), and N2 neutrophils. These cells suppress anti-tumor immunity, allowing the cancer to evade the body’s defenses. Single-cell analysis is revealing the heterogeneity within these populations and identifying potential therapeutic targets ¹.

Additional Inflammatory Mechanisms

The NLRP3 inflammasome and epigenetic modifications contribute to the perpetuation of inflammatory cycles within the TME. These mechanisms further exacerbate the pro-tumorigenic effects of chronic inflammation.

Cancer-Specific Examples

• Colorectal Cancer (CRC): Dysbiosis (imbalance in gut bacteria), NF-κB/STAT3 activation, and NLRP3 inflammasome activation are correlated with poor prognosis.
• Lung Cancer: Exposure to tobacco smoke and air pollution triggers COX-2/PGE2 and IL-6/STAT3 signaling. KRAS mutations can amplify immunosuppression.
• Breast Cancer: Obesity-associated inflammation drives the accumulation of MDSCs, and Tregs. C-reactive protein (CRP) levels can predict response to neoadjuvant therapy.

Immunotherapy and the Inflammatory Microenvironment

Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1/CTLA-4, has revolutionized cancer treatment, but response rates remain limited, ranging from 20-40% ¹. Elevated levels of IL-6 have been identified as a predictor of resistance to ICIs. The LAG-3 blockade (relatlimab) received approval in 2024, offering a new avenue for immunotherapy.

Other immunotherapeutic approaches, such as CAR-T cell therapy, have shown efficacy in hematologic malignancies but are often limited by the immunosuppressive TME in solid tumors. CRISPR-edited CAR-T cells are being developed to improve their persistence and function within inflammatory TMEs.

Personalized neoantigen vaccines and oncolytic viruses (like talimogene laherparepvec) are under investigation, and their combination with anti-inflammatory agents is being explored. Tumor-infiltrating lymphocyte (TIL) therapy has shown efficacy in melanoma, and CRISPR enhancement is in development to further boost its effectiveness.

Translational Advances and Therapeutic Strategies

Researchers are exploring several strategies to target inflammation in cancer:

• Drug Repurposing: Aspirin has been shown to reduce CRC risk and metastasis. COX-2 inhibitors are used in familial adenomatous polyposis (FAP). Statins are under investigation for their anti-inflammatory and anti-cancer effects.
• Cytokine Targeting: Clinical trials are evaluating the use of tocilizumab (anti-IL-6R), siltuximab (anti-IL-6), and infliximab (anti-TNF). Studies in 2025 combined IL-6 blockade with ICIs in pancreatic cancer.
• NF-κB/STAT3 Inhibition: Bortezomib, a proteasome inhibitor, suppresses NF-κB activation. Novel STAT3 inhibitors are showing promise in preclinical studies by reducing MDSCs.

Biomarkers and Personalized Medicine

Several inflammatory biomarkers, including CRP, IL-6, neutrophil-to-lymphocyte ratio (NLR), and pan-immune-inflammation value (PIV), can predict prognosis and response to immunotherapy. PD-L1 IHC, tumor mutational burden (TMB), and microsatellite instability (MSI) are also used as predictive biomarkers. Emerging biomarkers include circulating tumor DNA (ctDNA) and microbiome signatures.

Combining ICIs with other therapies – such as aspirin, VEGF inhibitors, chemotherapy, or radiation – is being investigated. Trials in 2024 are combining ICIs with microbiome modulators in CRC.

Future Directions

Emerging technologies hold significant promise for refining cancer treatment:

• Microbiome Modulation: Certain bacterial species, such as Bifidobacterium and Akkermansia, correlate with ICI response. Fecal microbiota transplantation (FMT) and CRISPR-based microbiome editing are under investigation.
• Artificial Intelligence (AI) and Machine Learning: AI is being used to predict prognosis, CAR-T resistance, and integrate imaging and text data for more accurate diagnosis and treatment planning.
• Gene Editing: CRISPR-Cas9 is being used to edit exhaustion genes in CAR-T cells and RNA editing for reversible modulation of gene expression.
• Single-Cell and Spatial Omics: These technologies are helping to identify MDSC clusters and resistance mechanisms, and their integration with AI is enabling dynamic TME mapping.
• Nanotechnology and Liquid Biopsies: Nanoprobes are being developed for TME monitoring, and ctDNA-based inflammatory signatures are being explored for noninvasive response prediction.

Future opportunities include antibody-drug conjugates (ADCs) delivering anti-inflammatory payloads, rational combination therapies targeting parallel pathways (e.g., NF-κB + STAT3), and germline pharmacogenomics for personalized anti-inflammatory treatment.

chronic inflammation plays a critical role in tumorigenesis, immune evasion, and therapy resistance. Integrating inflammation-targeting strategies with immunotherapy and biomarker-guided approaches offers a path toward personalized cancer care. Advances in microbiome modulation, AI, gene editing, and single-cell technologies position the field for transformative progress.